Clue:
Mentor Capital Initiates COVID-19 Related Investments
Press Release | 12/21/2020
Mentor Capital, Inc. (OTCQB: MNTR) announced that it has added a business segment that focuses on the vaccine and associated medical companies involved in the fight against SARS-CoV-2. The initial public companies in the small internal portfolio are Pfizer, Inc., Moderna, Inc., AstraZeneca PLC, and BioNTech SE. The majority of medical segment purchases from common share, accredited, and debt sourced funding by Mentor are targeted toward private company purchases. This is substantially reserved for those smaller firms supporting the battle against COVID-19 looking for public market liquidity. Mentor Capital, Inc. is not an investment company.
Mentor’s business move into the COVID-19 arena is a natural outshoot from the Company’s long prior history of financially supporting leading-edge immunotherapies in the fight against cancer. Mentor Capital, Inc. also sponsors a non-profit under the name “Antibody Badge.” Through AntibodyBadge.com, any vaccine manufacturer, government agency, or vaccine administrator, in bulk, or persons individually that receive the COVID-19 vaccine from Pfizer/BioNTech, Moderna, and AstraZeneca with others as approved, can request one-inch lapel pins that read “COVID-19 Antibodies.” Since the vaccines are reported to be about 90% - 95% effective, antibody badges could conveniently give peace of mind in supermarkets, restaurants, churches, and other casual gatherings, indicating that the wearer is vaccinated without the more significant intrusion of showing an electronic passport. Anecdotal survey indicates that approximately 24% more people would get the vaccine if the Antibody Badge lapel pin could be worn in lieu of a mask in casual settings.
News 
Market Data 
Discover 
